Home > Dermatology > EADV 2019 > Emerging Therapies > Biologics: increasingly used in paediatric dermatology

Biologics: increasingly used in paediatric dermatology

Presented By
Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands
Conference
EADV 2019
Biologics and cytokine blockers are increasingly used in children and adolescents with moderate-to-severe psoriasis and atopic dermatitis (AD). Data shows that they cause fewer side effects than systemic conventional therapies [1]. In adults, biologics targeting specific cytokines are effective, well-tolerated, and a safe alternative to conventional systemic treatments. At present, 3 biologics (i.e. etanercept, adalimumab, and ustekinumab) are approved in paediatric psoriasis and dupilumab is approved in AD. TNF-blockers and ustekinumab showed similar efficacy and tolerability compared with trials in an adult population [2-4]. In the meantime, long-term data from open-label extensions with TNF-blockers showed reassuring results. After 5 years, etanercept was still well-tolerated and efficacy was maintained in those who remained in the study for up to 264 weeks [5]. There were no opportunistic infections or malignancies. Similarly, 52-week data from ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on